Literature DB >> 23817516

Evolution of longitudinally extensive transverse myelitis in an aquaporin-4 IgG-positive patient.

Nasrin Asgari1, Hanne Pernille Bro Skejoe, Vanda A Lennon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23817516      PMCID： PMC3770200          DOI： 10.1212/WNL.0b013e318297ef07

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  2 in total

1.  Intractable vomiting as the initial presentation of neuromyelitis optica.

Authors:  Metha Apiwattanakul; Bogdan F Popescu; Marcelo Matiello; Brian G Weinshenker; Claudia F Lucchinetti; Vanda A Lennon; Andrew McKeon; Adam F Carpenter; Gary M Miller; Sean J Pittock
Journal:  Ann Neurol       Date:  2010-11       Impact factor: 10.422

2.  Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system.

Authors:  R D Broadwell; M V Sofroniew
Journal:  Exp Neurol       Date:  1993-04       Impact factor: 5.330
  2 in total
  19 in total

Review 1.  Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.

Authors:  Dominique Rosales; Ilya Kister
Journal:  Curr Allergy Asthma Rep       Date:  2016-06       Impact factor: 4.806

Review 2.  Neuromyelitis optica spectrum disorders.

Authors:  Eoin P Flanagan; Brian G Weinshenker
Journal:  Curr Neurol Neurosci Rep       Date:  2014-09       Impact factor: 5.081

3.  Neuromyelitis optical spectrum disorders presenting with isolated "inverted V" sign in area postrema.

Authors:  Chenguang Zhou; Yuanhong He; Xiaoya Gao; Yinghui Zhu; Zhiwen Chao; Xingping Wang
Journal:  Neurol Sci       Date:  2018-03-01       Impact factor: 3.307

4.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.

Authors:  Sven Jarius; Klemens Ruprecht; Ingo Kleiter; Nadja Borisow; Nasrin Asgari; Kalliopi Pitarokoili; Florence Pache; Oliver Stich; Lena-Alexandra Beume; Martin W Hümmert; Marius Ringelstein; Corinna Trebst; Alexander Winkelmann; Alexander Schwarz; Mathias Buttmann; Hanna Zimmermann; Joseph Kuchling; Diego Franciotta; Marco Capobianco; Eberhard Siebert; Carsten Lukas; Mirjam Korporal-Kuhnke; Jürgen Haas; Kai Fechner; Alexander U Brandt; Kathrin Schanda; Orhan Aktas; Friedemann Paul; Markus Reindl; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2016-09-27       Impact factor: 8.322

5.  Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease.

Authors:  Sara Salama; Majid Khan; Michael Levy; Izlem Izbudak
Journal:  Mult Scler Relat Disord       Date:  2019-01-10       Impact factor: 4.339

6.  Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.

Authors:  Eoin P Flanagan; Brian G Weinshenker; Karl N Krecke; Vanda A Lennon; Claudia F Lucchinetti; Andrew McKeon; Dean M Wingerchuk; Elizabeth A Shuster; Yujuan Jiao; Erika S Horta; Sean J Pittock
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

Review 7.  Pattern Recognition of the Multiple Sclerosis Syndrome.

Authors:  Rana K Zabad; Renee Stewart; Kathleen M Healey
Journal:  Brain Sci       Date:  2017-10-24

Review 8.  A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course.

Authors:  Jacqueline M Solomon; Friedemann Paul; Claudia Chien; Jiwon Oh; Dalia L Rotstein
Journal:  Ther Adv Neurol Disord       Date:  2021-05-09       Impact factor: 6.570

Review 9.  Hypersensitivity Responses in the Central Nervous System.

Authors:  Reza Khorooshi; Nasrin Asgari; Marlene Thorsen Mørch; Carsten Tue Berg; Trevor Owens
Journal:  Front Immunol       Date:  2015-10-07       Impact factor: 7.561

10.  Cerebrospinal fluid aquaporin-4-immunoglobulin G disrupts blood brain barrier.

Authors:  Nasrin Asgari; Carsten Tue Berg; Marlene Thorsen Mørch; Reza Khorooshi; Trevor Owens
Journal:  Ann Clin Transl Neurol       Date:  2015-05-29       Impact factor: 4.511
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.